Rollover Study of VX-770 in Cystic Fibrosis Subjects
NCT01117012 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 192
Last updated 2015-07-07
Summary
The primary objective of the study was to evaluate the safety of long-term VX-770 treatment in participants with cystic fibrosis (CF). The secondary objective of the study was to evaluate the efficacy of long-term VX-770 treatment in subjects with CF.
Conditions
Interventions
- DRUG
-
Ivacaftor
Sponsors & Collaborators
-
Cystic Fibrosis Foundation
collaborator OTHER -
Vertex Pharmaceuticals Incorporated
lead INDUSTRY
Principal Investigators
-
Edward McKone, MD · St Vincent's University Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 6 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-07-31
- Primary Completion
- 2014-05-31
- Completion
- 2014-05-31
Countries
- United States
- Australia
- Canada
- Czechia
- France
- Germany
- Ireland
- United Kingdom
Study Locations
More Related Trials
-
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
NCT00909532 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
NCT02070744 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
NCT02347657 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
NCT00457821 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation
NCT02565914 ·Status: COMPLETED ·Phase: PHASE3
-
Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation
NCT01946412 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)
NCT01614457 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation
NCT01614470 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
NCT03029455 ·Status: COMPLETED ·Phase: PHASE1
-
Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
NCT01531673 ·Status: COMPLETED ·Phase: PHASE2
-
Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
NCT03768089 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
NCT02508207 ·Status: COMPLETED ·Phase: PHASE2
-
Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor
NCT02544451 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
NCT03911713 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
NCT03277196 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
NCT02412111 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
NCT02742519 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
NCT02392234 ·Status: COMPLETED ·Phase: PHASE3
-
VX-770 for the Treatment of Chronic Bronchitis
NCT03251911 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
NCT02725567 ·Status: COMPLETED ·Phase: PHASE3
-
Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
NCT01225211 ·Status: COMPLETED ·Phase: PHASE2
-
Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects
NCT01208285 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
NCT02951182 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
NCT01161537 ·Status: COMPLETED ·Phase: PHASE2